NIH splits allergy institute into three—creating coordination risks
H.R. 1497 — NIH Reform Act · Filed by Chip Roy (R-TX) · 6 cosponsors · Introduced Feb 21, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill splits the National Institute of Allergy and Infectious Diseases (NIAID) into three separate institutes: one for allergic diseases, one for infectious diseases, and one for immunologic diseases. Each new institute will have its own director appointed by the President with Senate confirmation for 5-year terms, renewable once. The bill transfers relevant research authorities and programs from NIAID to the new institutes and updates all federal references accordingly.
Why we flagged it
The bill's core function is administrative reorganization of NIH structure—splitting one institute into three with new governance chains. It does not create new research programs, funding, or policy mandates; it redistributes existing authorities and creates new management positions.
What the text implies
- Splitting NIAID may fragment research on diseases with overlapping allergic, infectious, and immunologic components (e.g., fungal infections with allergic sequelae), potentially requiring new inter-institute coordination mechanisms not addressed in the bill.
- Creating three new director positions increases federal payroll and administrative overhead; no cost estimate or funding source is specified, raising questions about whether existing NIAID budgets will be stretched across three institutes or new appropriations are required.
The full analysis lists 4 implications of this text.
Who stands to gain
Pharmaceutical companies with allergy/immunology portfolios (BMY, JNJ, PFE); Biotech firms focused on infectious disease and immunology research; Contract research organizations supporting NIH-funded studies